Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$4.26 +0.2%	$3.96	$2.13 ▼ $10.00	$290.40M	0.58	839,129 shs	441,874 shs
LFCR Lifecore Biomedical	$7.49 -2.5%	$7.29	$3.68 ▼ $8.85	$277.36M	0.71	229,200 shs	118,062 shs
OCGN Ocugen	$1.02 +2.0%	$0.97	$0.52 ▼ $1.72	$297.87M	4.18	4.54 million shs	3.09 million shs
VNRX VolitionRx	$0.68 -0.2%	$0.63	$0.40 ▼ $0.94	$70.19M	1.2	208,210 shs	158,216 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	+2.90%	+7.58%	+32.30%	+95.41%
LFCR Lifecore Biomedical	0.00%	-9.76%	+7.93%	+24.01%	+54.43%
OCGN Ocugen	0.00%	-10.53%	-3.77%	+50.64%	-38.55%
VNRX VolitionRx	0.00%	+1.09%	-26.63%	+41.21%	-4.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.0715 of 5 stars	3.5	1.0	0.6	3.3	0.6
LFCR Lifecore Biomedical	0.96 of 5 stars	1.3	1.0	1.8	4.2	0.6
OCGN Ocugen	1.2191 of 5 stars	3.5	1.0	1.7	0.0	0.0
VNRX VolitionRx	2.2108 of 5 stars	3.5	0.0	2.3	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	252.11% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	6.81% Upside
OCGN Ocugen	3.00	Buy	$6.00	488.24% Upside
VNRX VolitionRx	3.00	Buy	$3.50	418.52% Upside

Current Analyst Ratings Breakdown

Latest VNRX, OCGN, CRVS, and LFCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/24/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/24/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.51 per share	N/A
LFCR Lifecore Biomedical	$128.26M	2.16	N/A	N/A	$0.37 per share	20.24
OCGN Ocugen	$4.05M	73.55	N/A	N/A	$0.10 per share	10.20
VNRX VolitionRx	$1.31M	53.65	N/A	N/A	($0.11) per share	-6.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$62.29M	-$0.98	N/A	N/A	N/A	N/A	-24.04%	-13.90%	8/5/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.19	N/A	N/A	N/A	-1,271.12%	-223.00%	-92.20%	8/1/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, OCGN, CRVS, and LFCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.0250	N/A	N/A	N/A	$35.36 million	N/A
8/5/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	N/A	N/A	N/A	N/A	N/A
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	$0.35 million	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	4.90	4.90
LFCR Lifecore Biomedical	66.36	2.71	1.59
OCGN Ocugen	1.74	2.60	2.60
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
LFCR Lifecore Biomedical	83.36%
OCGN Ocugen	10.27%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	31.30%
LFCR Lifecore Biomedical	32.20%
OCGN Ocugen	4.29%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	46.83 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
OCGN Ocugen	80	292.03 million	279.50 million	Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

VNRX, OCGN, CRVS, and LFCR Headlines

Recent News About These Companies

VolitionRx's (VNRX) "Buy" Rating Reaffirmed at D. Boral Capital

July 20 at 2:12 AM | americanbankingnews.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

July 12, 2025 | americanbankingnews.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, OCGN, CRVS, and LFCR Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$4.26 +0.01 (+0.24%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.22 -0.04 (-1.06%)

As of 05:45 AM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Lifecore Biomedical NASDAQ:LFCR

$7.49 -0.19 (-2.47%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.49 0.00 (0.00%)

As of 07/18/2025 04:04 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Ocugen NASDAQ:OCGN

$1.02 +0.02 (+2.00%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.06 +0.03 (+3.43%)

As of 06:03 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

VolitionRx NYSE:VNRX

$0.68 0.00 (-0.19%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$0.68 +0.00 (+0.44%)

As of 07/18/2025 04:15 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time